Methods of murine astrovirus detection

Abstract

Novel murine astroviruses, and methods of detecting the viruses are disclosed. Also disclosed are uses of the viruses and infected animals as model systems for discovery and development of vaccines and therapies for diseases caused by or associated with astrovirus infection, including human astrovirus-based diseases.

Claims

1. A method of detecting the presence, absence or quantity of a murine astrovirus in a mouse sample, the method comprising: providing a sample from a mouse comprising or suspected of comprising a murine astrovirus wherein the mouse sample is selected from the group consisting of a fecal sample, a vomitus sample, a tissue sample and a blood sample; synthesizing cDNA using sample RNA as a template; contacting the cDNA with at least one primer comprising a sequence having at least 95% sequence identity with TABLE-US-00006 (SEQIDNO:6) CCAAGAAAGAGGCACTAGTGGCACTC (SEQIDNO:7) GTTTTTTTTTTTTTTTTTTTTTGCCAATTTTTATGCCAATTATATCACCC or (SEQIDNO:9) GTGTCACTAACGCGCACCTTTTCA; and performing a quantitative PCR assay comprising the cDNA and the at least one primer, thereby detecting the presence, absence or quantity of a murine astrovirus nucleic acid.

2. A method of detecting the presence, absence or quantity of a murine astrovirus in a mouse sample in accordance with claim 1, wherein the at least one primer that has at least 95% sequence identity with SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:9, has 100% sequence identity with SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:9.

3. A method according to claim 1, wherein the sample is a fecal sample.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

(2) FIG. 1A-B illustrates a comparison between identified astrovirus sequences.

(3) FIG. 2 illustrates a schematic of the identified astrovirus genomes.

(4) FIG. 3 illustrates detection of astrovirus in immunocompromised mice by PCR.

(5) FIG. 4A-C illustrate that adaptive immune response is required to control astrovirus replication.

(6) FIG. 5A-B illustrate that astrovirus can be detected in commercially available mice.

(7) FIG. 6 illustrates antibody responses during marine astrovirus infection.

(8) FIG. 7 illustrates genetic diversity of murine astroviruses identified by next generation sequencing.

(9) FIG. 8 illustrates kinetics of murine astrovirus shedding.

(10) FIG. 9 illustrates an AstV (astrovirus virus-like particles) ELISA validation.

(11) FIG. 10 illustrates a second AstV (astrovirus virus-like particles) ELISA validation.

(12) FIG. 11 illustrates an AstV (astrovirus virus-like particles) ELISA screen.

DETAILED DESCRIPTION

(13) Methods

(14) Methods and compositions described herein utilize laboratory techniques well known to skilled artisans. Such methods and compositions can be found described in laboratory manuals such as Sambrook, J., et al., Molecular Cloning: A Laboratory Manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2001; Spector, D. L. et al., Cells: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1998; Harlow, E., Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1999; Ausubel, F. M., et al., ed., Current Protocols in Molecular Biology, Wiley Interscience, 2003; Nagy, A., et al., Manipulating the Mouse Embryo: A Laboratory Manual (Third Edition), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2003. Methods of administration of pharmaceuticals and dosage regimes, can be determined according to standard principles of pharmacology well known skilled artisans, using methods provided by standard reference texts such as Remington: the Science and Practice of Pharmacy (Alfonso R. Gennaro ed. 19th ed. 1995); Hardman, J. G., et al., Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, McGraw-Hill, 1996; and Rowe, R. C., et al., Handbook of Pharmaceutical Excipients, Fourth Edition, Pharmaceutical Press, 2003. These publications are incorporated herein by reference, each in its entirety.

(15) As used herein, the singular forms a, an and the are intended to include the plural forms as well, unless the context indicates otherwise. Examples presented herein are illustrative and are not intended to be limiting to the scope of any claim.

(16) Sequences of murine astroviruses of the present teachings include the following:

(17) TABLE-US-00002 >Mouse_Astrovirus_STL_CY1_20120531_Update (SEQIDNO:1) CCAAGAAAGAGGCACUAGUGGCACUCCUGCUGCUAGUAAGUCUGACAUGGCCCUG CGUAAGGAGUAUACUUCCCUUGUGGACCAAGCGGUCGACGCUGGGAAUUACCUG GCCCGCUGCCAGUUGCCAACUACGGCAAUUCUGCUGCUGCGCAAUAUGCCUGACC ACUAUCCUAACCGGCCUUGGUCUGUCCAUUCGACCCCCCGCCAUUUGGUCUAUCC CUCAACAACGGAUGAUCCAAAGACGCGGGUUAUAACAGCCUCCUCCGUCACAGUG GAGGAUGAAUGGGUGACCUAUGUCUGGACCGGCGCGCGCUGGCAGCAGGUGGCA ACGGCCCCUGACUGUGGAAAAACGAUCCUGGUCUGUGCCCUCCUGAACGAACAUA AGCGGCUCAAGGAUGAGAAUGCAAGCCUUAAACUUGCCAAGGCGAAUUUGGAGG UUGAUAACACCACACUGCGGGUGGCGUCAGCGGCCAUUACCAACUCGGCCCCUCG CCGUUCGCGCCUCCCUUGGAUCCUGGCACUCUUGGCUGUGCUUUUCUCCCUCCUC ACGACCUCGGCUGCCUUUGAAACCAGCUCUACCUCACGGAGCUAUGCCCCUGAGG AUAUUGCUAGGCACUCUGAGGAUUUGAACACCUUUAUUGAGAACGCUUUGAGGG UGAACCACACACGCUCCUACACAGAGUACACCUACCAACUGUACGCCACACAUGC UCAGACUUUCUUGGACCGCAUGGCCUUGACAUUUAACACCUGGCAAGCUUAUGAU CCGCACUUCUUUGCGAAAACACCCUUGCAAAGUGCGCUUCUGAGUGUCCUCCAGU AUGUAACACCCUGGACGUGGGAGAUAGCCCUUACGGGCUUGGUAUUGGCGCUCA UGCUAGCGGAAAACUCUAGCCCUUGGUCGCUGCUCUACCUGGCCUGUGCUACUCU CACAAGGACCCGCUUUGCCCUCUUGGCCGUGGCGCCCUUCCAGACACGCUACACG ACGGCUGUCACCGUUGCCGCCUCGGUGCUCUACGCACUCGACCCCUUGGUCGCAG UGGCGUGCCUGGUGCUACACCUCUUUCUCCUGGCAGUGGUGGGGCUCUUCAUGGA GGAUACCUCCUAUGUCCAAAACUUGAAGGGCGCCUUCCUGCUGCUAUGCGCCUUC UUCGGCCAUGCCCUCUGUGCCUCUUCGGAGUGAGCUCGGCGCCAGUCACAACAC UAGCUGUUGCCUGGCGGAUCUGGCGGCUACUCUCUCGUGCCGGAACAACAGGCAC CGUGGAGGUGCGCAAUGAAGAAGGCAAGGUGGUCUCAAAACAGACCACGCAACCC AACUUCCUCUUCCGCUUCAAGCAGGCGUUGAGGAGGAUGAGACAACUCAGAACGA CCCAGACCCCCCUAGCGCGCGUCAAUCCUGAUGCGCUCUGCCACAUCAGCGUGGC CGGGGCGAAAGGCACUGGCUUCUUUUGUGGUAACUACGCUGUGACAUGUGCACA CGUAGUCGGGAGUGAGACAGUCGUCAACCUGUGCUAUAAAGGCCGUAACUAUCA GGCCCCAGUGAAGAAAAUCCUGGAGCAAAAGGAUGUGGCACUCAUUCCCAUACCU GCGGGGAUAACACCACCCCGCUUGAAGAUCUCCAAGAAGCACUGCUGCGACUGGG UCUGUGUCUGUGCCCCCGACGGUGAUGGUGCCUACCUAACUGCUGUGACUGAGGG UUGCGAGCAUGAUGGUCACUACUCCUAUGCCUGCCCGACGCGGGAUGGGAUGUCU GGCGCUCCUCUGUUAGACAUAGAUGGCCAUGUUCUUGGGAUACACACUAACAACA CUGGCUACACUGGUGGUGCCCAACGCCUCGACCUUGAGGACAUAGUUGAAGCCCC CAAGCCAAAUCCCAAGCAGCUCGCCCUCGAGAGGGAGAUUGAAGAACUGAAAAAG CAGCUUGCGGCCCUGCAGCCUGAACCACCUAGGCCUGAGCCCGUGGCUGCCCCUC CCUCACCCGUUCAGCCCGGCCCCCUAGUGGUUCCAACUACCUGCCCCCCUCCAGCC CCACCGGCACCAACUGUGGCCCCUGCUCCUGUGGCCCCCAGCCCUGUGGCGCACU AUGUGGUCAAACCCACCCAAAUUCCACCUAUGCAACAAAGCCUAACAACUAGUGA UGUGGUGGAUCUUGUGCGUGCGGCAAUGGGUCGUGAGAUGCAAAUCCUGCGGGA CGAGCUGAACCUGAUGAAUCAGGCUAAAGGGAAGACCAAACGUGGCCGUGGGAA GAAGCAUACCAUCGGGGCUCGUGUUGGUGGCCGUCGCAGACAGCGUGGGCCUGCC UUCACCGAGGAGGAGUACAAGGAGAUGCUGGACCAAGGGAUUGACCCCGAUGAG AUCAAGCGCCUAGCCGAAGACCUCUGGGAGGACCAGACUGGCUUCCCGGAGUGGA GUGACCCUGAGUUCUCUGAUGAGGACGAUGGUUGGACACCAAAGACCCAUGACU GGCUAGACUUUGAUUAUGAGGAUGAUUUGGAACAAACUUACGUCCCIUGGUCCCU GGGCCCAGAAAUGCAAGAUACCUCUCGUCGACUACGUCAAGAAGAUCUUUGACAA AGGCUCCGUUGAUGAGAUGUUACAAAAUCUUGCCCCUCUGGAGAAGAAGCUCUG UAGGAAACAACUUGAGGCCGUUCGCCAGGCAAAAACUGAUAUCGAGCUCUCUGU UGCACUUGGCGCUUUGGAUCGUCGUGCUGCCGAUGUGGGCAUGCAGCCCUUUACA CCAGGGCUAGAGUAUAAACAAGCUGUUCCAAAAAACGCCAAGGGCCCCCGCAAGG GGGCAAAAGAUCAGGGCUCGAAGACUGGAAAGAACUAAGGCAGCCCCCCUUUCGC CUCCUGGUACCCCAGCCUUACCCUGUUGUCUGCAGCUUACCCCUGGACCGGCCCA UCUAUGACAACGAUGAGCCUAAAGAUCCACUUCUGGGGGUGUUGCCACAUGUAG ACUAUGAGGGUAACUUUGCACCAACAACCUGGGGAGGCGCAGCUUACGCGAAGA GUUUCGAGAAGUUCACGUAUGCUCAACCUGUGGACUUCGAAAAGCACUAUCCUG UAGAAACUCAGUUCGCUGACUGGGCCUGGCGAGUCCACCACGCUUACCUGGAAGG CACUCGGGUAUGCCACAUCAUGUCUACAGAGAAAAAUACCGACUCAACCCCUGCC UACCCCAAAUGCCUGGACUACUCCACCGAGGCCGACUACCUAGAGGAACAUGGCU GGGAGCCCUAUGUCAACGCUUUCCGUGCCAUUGACUCCGGGGAGCGGCCCCAGGU UCUCUGGUUCCUCUUCUUGAAGAAGGAGAUUCUCAAACAAGAGAAGAUUCGCGA UUCAGACAUUCGUCAGAUUGUCUGUUCAGAUCCCAUCUAUGCGCGGAUCGGAGCU UGCUUCGAACAACAUCAAAACCAUCUCAUGAAGCAAAAAACAGAGACCCAUUCCG GGCAAUGUGGCUGGUGCCCCCUGAAGGGGGGCUUUGAGGCAAUGUGCCACCGUCU UGCCUCUAAGCAGGGUGUCUUUGUGGAAUUUGACUGGACACGCUUUGAUGGAAC AAUCCCCGUACAACUCUUCCGCAGGAUAAAGAAGCUCCGCUGGUCCAUGAUUUGU CCCGAACAUCAGCAGCGCUACGGGCACAUGUACCAGUGGUAUGUUAACAAUCUCU UGCACCGCUACACCGUGCUGCCCUCAGGUGAGGUGACCAUCCAAACUCGUGGCAA CCCCUCAGGGCAAAUCUCAACAACAAUGGAUAACAACAUGGUUAACUACUGGCUU CAGGCAUUUGAGUUCUGCUACUUCUUUGGCCCUGAUAAAGAUCUCUGGCGGCAG UAUGAUACUGUCUGCUAUGGUGAUGACCGGCUUACGCGCUACCCUGUGCUACCAC CCCAUUACAUCGAGCGGGUGGUCGCCAUGUACAAGGACAUCUUUGGCAUGUGGG UUAAACCUGAAAAGGUGCGCGUUAGUGACACCCUGGUUGGUCUCACCUUUUGUG GCUUUAGAAUAGGGGAGCACUAUUUGCCCUAUCCUGCACAGGAAGACAAACUCU UUGCCGGCCUCGUCCGGCCAGUGAGGAAAUUGGCUGACUUUAAAACACUCCAUGG GAAACUCUUGAGCCUGCAGCUUCUGAUGCACUUCCACCCUCCGAGUCCCUUUAAG GACUACUUGGAGAUGUGCUUGGCAAACACCGCCAAGUACUGCCCGGAACUUCCGG CGCGGUUUUCAGAGCGUCAGAUGGACAAGCUUUGGAGGGGAGGACCAAAAGCUG UUCAUGGCUAAGGCCAAACAACAACAGAAAAAUGCCACGACCGUCACUACUACAA CUGUCACUGGUCGCAGUAGUCGGCGGUCUCGCAGGCGCUCUGUACGGCGCCGCGC UGCAGGCCCUUCUAACCCCCCAACAAAGACAACAACUGUUCGGACUGUUUUUCGC CGCACUGCCCGGCCUCGCGGUGAUCGCCGCAGGAGUAGGAAUGCUCAGCGGCAGG CUCCUCGCGAGGUUGUUCAGACGGUUACGGCGACCCUCGGAACGGUUGGCGCGAA CCAGGGCAAUCAGGUCGAGCUUGAGAUGGCAGCGCUCCUCAACCCAGCGCUAAUU AAAGAAACAACUGGCUCAAACGCCUUCGGACCACUCCAGAUGUAUGCCUCCACGC AUGCCAUGUGGAAAGUGGAUAGGCUCACACUCAAGCUCACCCCUCUGGUCGGCGC CUCUGCUGUUUCCGGUACAGCGGUCCGUGCCUCACUGAAUAUGACAUCUGGGCCC GCCGCGCCCGCCUGGUCAGCCUUGGGCGCGCGGAAGCAUGUGGACACCAAUCCUG GUCGGCCGGCUUCCUUCACCCUCACAGCCGCCGAUGUACCUGGCCCCAAGCAGGG UUGGUUCUUUACUAAUACUAAGCAGGAGGCCGGCUUUACAGUCGGCGGGGCCAU UGAGAUCCAUACCCUCGGCAAGACGAUGUCAACCUACCAGAACUCAGCCUAUACG GGCCCACUCUUUCUUGCCGAGGUCACAGGUACCUGGAGGUUUAAGAACUACGAGC CCCAGCCCGGCUUGCUCAACCUCCUCAAGACCGAGGUUAAAGAGCCUGCGGGCAC UGUGAAGGUACACUCCAAACCUGGAGAACCUGUCACGCUCUCCAUCCCUCAAGCA GGGACCUUUGCUGGCCUAGAGAGGCUAAAUCCAACAGCCUCGGCCACACCAGGUG AGAUCAUCUGGGAGGUAGUGGAUUCCGCUGCGAAUGCGGUCUCCGGCUUGCUUCC UCAACCCUGGCAGUGGCUUUUUAAAGGCGGCUGGUUCUUCCUGAAAAGAAUUGC CAACCGGAAACCUGUUGGUGCCGCCAGUGUGGCGGGUGAACCUGAUGGAGGUGA AGUGACUUUCCGCGUGUACGCCAGUAUCGCGGAUGCCCAGAAUGAUGUGCCCUGU AUUGCCAGCUCGGCGGCCUCCACUCAAUCCAUACAGACGGAGGGUCUCAAGAUCU CCCAGGUGACUCCUGGGACCAUUGGUAUGCCUGAAACUGCAGUAGCCACACACAA CAUGGCUCCACCACCCGAGUCCGGACCCUAUACCUAUCAAGGGCCCACCUUGGAG GCUGCUGCUCCUUUGCACGCCCCCAAGUAUACACAGUGGACUAUUGUAGAUGCUG GUACCUCCCAGGAGCAGGCCCGCCUGCGCUCCGGGGUGGUCCCAGCAGAGCAGAC CUCAGCCUGGUCGAGCUGUACUCUGGAGCUCCCAGGCACCUUCCUCCAGAAUAUG UAUGAGAUUGAUCCCCGUGAUAUUGCAGCCGGUACCUUUCCCAUCAAUCACUGGA ACGUGAGCACCUCGCGGCUCACGCGGCUUGGCACCGCCUACGGUUGCAAUCAGGC GCGGGUCCGCACCUAUGGGGAGGGAGUCCCGCAUGUGGUUAUCUCUACCACUUCU GUCCUCUGGAUGGCCGACGUUUCCACAGGGUGGAACUAUGACAACUUCUCCGCUG CCAUCUGGAAUCCCAUAGUGGUAGCUGGGCCAAACGUCCAUGGGACUGAACAGGG CAUUCCUCUCACCCGGGGAACCCUCAACUGGCCCGGGGGCGAUAGGAAUCGCUGG CCCUACCGCAACCAGAUUGAGAAGGGUCACUGGUAUGUGACCUUCUGGACUCAGU ACGAUCCUGAUGAGUGGGUCUGGUUGGAUGAGUUCCAUCUCCAGUUCACCUUGC AACCGGGCACGCACACCCCCACUGAAAACCAUUACUGGGAUGUAACAGCAGACAG CUUAGGUACUGGCCUCUGGGGCCUCCGGGACCUUGUGUUCUACCCAAUAGGUACC CAGCCCAGGAUAGUGAUACCAAACACUGGGCCUACCAGCUCCCAUGUGACCUUCG ACCUCCCCCCGGGUGAGGGCGAAGAUUACUCUACAGAUGAGGAAGGCGAGUCCGA UGAGGGAGCUGAGGAUGAUGAAGGAAAUCCCCUUGAAUUUGACCACCCAUUAGA CGGCGAUCUCUCGCAACCCCCCGCCGCCGUCCUGAAAGAUCUGACCUACAAGGGG CGUAAUCUCGCCAAUGAAUUGUGGAGUACGGGGGUGCCAGAUGCGAAGGCCUGG CUGGCGGGACAGACCAUCGACCCGUCGCCAUCCUUUCGCCGCUGGCGAGAGACUU UUCAAAAAGCGCUCCAGCGUGGUGUAGCACCCCUGGAAGCGCAUGAGCUCGCUAC UAGCGAGUUCCUUGCUCAAAGAGAAAGCCGCGGCCACGCCGAGUAGGAUCGAGGG UACAGCUUUCUCCCCUGCUUUUCUGCUUCUUUCUGUGCUUUGGUGUUACUUUAGG GUGAUAUAAUUGGCAUAAAAAUUGGCAAAAAAAAAAAAAAAAAAAAA >Mouse_Astrovirus_STL_CY2_20120531_Update (SEQIDNO:2) CCAAGAAAGAGGCACUAGUGGCACUCCUGCUGCUAGUAAGUCUGACAUGGCCCUG CGUAAGGAGUAUACUUCCCUUGUGGACCAAGCGUUCGACGCCGGGAACUAUCUGG CCCGCUGCCAGUUGCCAACUACGGCAAUUCUGCUGUUGCGCAACAUGCCCGACCA CCACUCCAAUCGGCCCUGGUCUGUCCAUUCAACUCCCCGCCACUUGGUCUAUCCC UCAACAACGGACGACCCAAGGAUGCGGGUUAUAACAGCCUCCUCCGUAACAGUGG AGGAUGAAUGGGUGACCUAUGCCUGGACCGGUGCGCGCUGGCAGCAGGUGGCAA CGGCCCCUGAUUGCGGGAAGACGAUCCUGGUCUGCGCCCUCCUGAACGAACAUAA GCGGCUCAAGGAUGAGAAUGCAAGCCUCAAACUUGCCAAGGCGAACUUGGAGGU UGAUAACACCACACUACGGGUGGCGUCGGCGGCCAUCACCAACCCGGCCCCUCGC CGCUCGCGCCUCCCCUGGAUCCUGGCACUCUUGGCUGUCUUCUUCUCCCUCCUCA CGACCUCGGCUGCCUUUGAAACCAGCUCUACCUCGCGGAGUUAUGCCCCUGAGGA UAUUGCUAGGCACUCUGAGGACUUGAACACCUUUAUUGAGAACGCUUUGAGGGU AAACCAUACACGCUCCUACACGGAGUACACCUACCAACUGUAUUCCACACAUGCU CAGACUUUCUUAGAUCGCAUGGCCUUGACAUUCAACACCUGGCAAGCCUAUGAUC CGCACUUCUUUGUGAAAACACCUCUGCAAAGUGCGCUUCUGAGUGUCCUCCAGUA UGUAACACCCUGGACGUGGGAGAUAGCCCUUACGGGCUUGGUGCUGGCGCUCAUG CUAGCAGAGAAUACUAGCCCUUGGGCGCUGCUCUACCUAGCCUGCGCUACUCUCA CAAGGACCCGCUUUGCCCUCUUGGCCGUGGCGCCCUUCCAGACACGCUACACGAC GGCUGUAACUAUUGCCGUCUCGGUGCUCUACGCACUCGACCCCUUGGUCGCUGUG GCGUGCCUGGUGCUACACCUCUUUCUCUUGGCAGUGGUGGGGCUCUUCAUGGAGG ACACCUCCUAUGUCCAAAACUUGAAGGGCGCCUUUCUGCUGCUAUGCGCCUUCUU UGGCCACGCCCUCUGCGCCCUCUUCGGAGUGAGCUCGGCGCCAGUCACGACACUG GCUGUCGUCUGGCGAAUCUGGCGGCUACUCUCUCGUGCCGGAACAACAGGCACUG UGGAGGUGCGCAAUGAAGAAGGCAAGGUGGUCUCAAAACAGACCACACAACCCA ACUUCCUCUUCCGCUUCAAGCAGGCGUUGAGGAGGAUGAGACAACUUAGAACGAC CCAGACCCCCCUGGCACGCGUCAAUCCUGAUGCGCUCUGCCACGUCAGCGUAACC GGGGCGAAGGGCACUGGCUUCUUCUGUGGUAACUAUGCUGUGACAUGCGCACAC GUAGUUGGGAGUGAGACAGUUGUCAACCUGUGCUAUAAAGGCCAUAACUACCAG GCCCCAGUGAAGAAAAUCCUGGCGCAUAAGGAUGUGGCACUCAUUUCCAUACCAA CGGGGCUAACACCACCCCGCUUGAAGAUCUCUAGGAAGCACUGCUGCGACUGGGU CUGCGUUUGUGCCCCCGACGGUGAUGGCGCCUACCUAACCGCUGUAACUGAGGGU UGCGAGCAUGAUGGUCACUACUCCUACGUCUGCCCGACGCGGGAUGGGAUGUCUG GUGCUCCUCUGCUAGACAUAGAUGGCCAUGUCCUUGGGAUACAUACCAACAAUAC UGGCUAUACUGGUGGUGCCCAACGCCUCGACCUUGAUGAUAUAGUUGAGCCCCCC AAGCCAAGUCCCAGGCAGCUCGCCCUCGAGGCGGAGGUUGAAAACCUGAGAAAAC AGCUCGAAAGUCUGCGGUCUGAACCCUUUAGGCCUGAGUCCGUGGCUGCCCUCUC UUCAACCGUGCAGCCCGGCCCCCUAGUGGUUCCAACUACCUGCCCUCCUCCAGCCC CACCGGCACCAACUGUGGUCCCUGUUCCCGUGGCCCCUAGCCCUGUGGUUAAACC CACCCAAACUCCACCUAUGCAACAAAGCUUGACAACUAGUGAUGUGGUGGAUCUU GUGCGCGCGGCAAUGGGUCGUGAGAUGCAAAUCCUGCGGGACGAGUUGAACCUG AUGAAUCAGGCUAAAGGGAAGACUAAGCGUGGCCGUGGGAAGAAGCACACUAUC GGGGCUCGUGUUGGUGGCCGCCGCAAACAGCGUGGGCCUGCCUUCACUGAAGAGG AGUAUAAGGAGAUGCUGGACCAAGGGAUUGAUCCCGAUGAGAUCAAGCGUCUAG CUGAAGACCUCUGGGAGGACCAGACUGGUUUCCCAGAGUGGAGUGAUCCUGAGU UCUCUGAUGAGGACGAUGGCUGGACACCAAAAACUCAUGAUUGGCUAGACUUUG AUUAUGAGGAUGACUUGGAACAAACCCAUGUCCCUGGUCCCUGGGCCCAGAAAUG CAAGAUACCUCUCGUCGACUAUGUCAAGAAGAUCUUUGACAGAGGCUCUGUUGA UGAGAUGUUACAAAAUCUUGCCCCCCUGGAGAAGAAGCUCUGUAGGAAACAGCU CGAGGCCGUCCGCCAGGCAAACACUGAUAUCGAGCUUUCCGUUGCACUUGGCGCC UUGGAUCGUCGUGCUGCCGAUGUCGGCAUGCAGCCCUUUACACCAGGCCUAGAGU ACAAACAGGCUGUUCCAAAAAACGCCAAGGGCCCCCGCAAGGGGGCAAAAGAUCA GGGCUCGAAGACUGGAAAGAACUGAGGCAGCCCCCCUUUCGCCUCCUGGUACCCC AGCCUUACCCUGUUGUCUGCAGCUUACCCCUGGACCGGCCCAUCUAUGACAACGA UGAGCCCAAAGAUCCGCUUCUGGGGGUGUUGCCACAUGUGGACUACGAGGGUAA UUUUGCACCAACAACCUGGGGAGGCGCAGCCUACGCGAAGAGUUUCGAGAAGUUC ACAUACGCUCAACCUGUGGACUUCGAAAAGCACUAUCCUGUAGAAACUCAGUUCG CUGACUGGGCCUGGCGAGUCCAUCACGCCUAUCUGGAAGGCACUCGGGUCUGUCA CAUCAUGUCUACAGAGAAAAAUACCGACUCGACCCCCGCCUACCCCAAAUGCCUG GACUACUCCACCGAGGCCGACUACCUGGAGGAACAUGGCUGGGAGCCCUAUGUCA ACGCCUUCCGUGCCAUCGAUUCCGGGGAGCGGCCCCAGGUUCUCUGGUUCCUCUU CUUGAAGAAGGAGAUUCUCAAACAAGAGAAGAUUCGCGACUCAGACAUUCGUCA GAUUGUCUGCUCAGAUCCCAUCUAUGCGCGGAUCGGAGCUUGCUUCGAACAACAU CAAAAUCAUCUCAUGAAGCAAAAAACAGAGACCCACUCCGGGCAAUGUGGGUGG UGCCCCCUGAAGGGGGGCUUUGAGGCAAUGUGCCAUCGUCUUGCCUCUAAGCAGG GUGUCUUUGUGGAAUUUGACUGGACACGCUUUGAUGGAACAAUCCCUGUACAAC UCUUCCGCAGGAUAAAGAAGCUUCGCUGGUCCAUGGUUUGCCCCGAACAUCAGCA GCGCUACGGGCACAUGUACCGGUGGUAUGUUAACAACCUCCUGCACCGCUACACC GUGCUGCCCUCAGGCGAGGUGACCAUCCAAACUCGUGGCAACCCCUCAGGGCAAA UCUCAACAACAAUGGAUAAUAAUAUGGUUAACUACUGGCUUCAGGCAUUUGAGU UCUGCUACUUCUUUGGCCCCAAUAAGGAUCUCUGGCGGCAGUAUGAUACUGUCUG CUAUGGUGAUGACCGGCUCACGCGCUACCCUGUGCUACCGCCCCACUACAUCGAG CGGGUGGUCGCCAUGUAUAAGGACAUCUUUGGCAUGUGGGUUAAACCUGAAAAG GUGCGCGUUAGUGACACUCUGGUUGGUCUCACCUUCUGUGGCUUUAGAAUAGGG GAGCACUAUUUGCCUUAUCCUGCACAGGAAGAUAAACUCUUUGCCGGCCUCGUCC GGCCAGUGAGGAAAUUGGCUGACUUCAAAACACUCCAUGGGAAACUCUUGAGCC UGCAGCUUCUGAUGCACUUUCAUCCUCCGAGUCCCUUCAAGGACUACUUGGAGAU GUGCCUGGCAAACACCGCCAAGUACUGCCCGGAACUUCCGGCGCGGUUUUCAGAG CGUCAGAUGGACAAGCUUUGGAGGGGAGGACCAAAAGCUGUUCAUGGCUAAGGC CAAACAACCACAGAAAAAUGCCACGACCGUCACUACUACAACUGUCUCUGGUGGC AGUAGUCGGCGGUCUCGCAGGCGCUCUGUACGGCGCCGCGCUACAGGCUCUUCUA ACCCCCCAACAAAGACAACAACUGUUCGGACUGUUUUUCGCCGCAAUACCCGGCC UCGCGGUAAUCGCCGCAGGAGUAGGAAUGCUCAGCGGCAGGCUCCUCGCGAGGUU GUCCAGACGGUUACGGCGACCCUCGGAACGGUUGGCGCGAACCAGGGCGAUCAGG UCGAGCUUGAGAUGGCAGCGCUCCUCAGCCCAGCGCUGAUUAAGGAAACAACUGG UUCAAACGCCUUUGGGCCACUCCAGAUGUAUGCCUCACGCAUGCCAUGUGGAGA GUGGACAGGCUCACACUCAGGCUCACCCCCCUGGUCGGCGCCUCUGCCGUUUCCG GCACAGCAGUCCGUGCCUCACUGAACAUGACAUCUGGGCCCGCUGCGCCCGCCUG GUCAGCCUUGGGCGCGCGGAAGCAUGUGGAUACCAACCCUGGUCGGCCGGCUUCC UUCACCCUUACAGCCGCCGAUGUACCUGGCCCCAAGCAGGGCUGGUUCCUUACUA ACACUAAGCAGGAUGCCGGCUUUUCAGUCGGCGGGGCCAUUGAGAUACACACCCU CGGCAAGACGAUGUCAACUUAUCAGAAUAAAGCCUAUGAUGGCCCACUUUUUCU UGCCGAGGUCACGGGCACCUGGAGGUUUAAGAACUAUGAGCCCCAGCCCGGCAUG CUCAACCUCCUCAAGACCGAGGUCAAGGAGCCCGCGGGUACUGUGAAGAUCCACU CCAAGCCUGGAGAACCUGUCACGCUCUCCAUCCCUGAAGCAGGGACCUUUGCUGG CCUAGAGAGGCUAAAUCCAACAGCCUCGGCCACGCCAGGUGAGAUCAUCUGGGAG GUAGUGGAUUCCGCCGCGAAGGCGGUUUCCGGCUUGCUUCCUCAACCCUGGCAGU GGCUCUUUAAAGGCGGCUGGUUUUUCCUGAAAAGAAUUGCCAACCGGAAACCUG UUGGCGCUGCCAGUGUGGCGGGUGAACCUGAUGGAGGUGAGGUGACCUUCCGCG UAUACGCUAGUAUCGCGGAUGCCCAGAAUGAUGUACCCUGUAUCGCCAGCUCGGC GGCCUCUACUCAAUCCAUACAGACGGAGGGGCUCAAGAUUUCCCAGGUGACUCCU GGGACCAUUGGCAUGCCUGAAACUGCAAUUGCCACACAUAAUAUGGUCCCACCAC CCGAGUCCGGACCCUACUACUAUCAGGGGCCCACCUGGAGGCUGCUAUUCCCUU GCGCGGCCCCAAGUAUACACAGUGGAUUCUUGUGGAUGCCGGACGCUCCCAGGAA UCGGCCCGCCUCCAUUCCGGGGUGGUCCCGGCAGAGCAGACCUCGGCCUGGUCGA GCUGUACCUUGGAACUCCCAGGCACUUUCCUCCAGAAUAUGCAUGAGAUUGAUCC CCGUGAUGUUGCAGCCGGUACCUUUCCCAUCAACUACUGGAAUGCGAGCACCUCG ACGCUCACGCGGCUCGGUACCGCCUACGGUUGCAAUCAAGCGCGGGCACGCACCU AUGGGGAGGGAGUCCCGCAUGUGGUCAUCUCCACCACCUCUGUCCUCUGGAGGGC CGAUGUCUCCGAAGGGUGGAACUAUGACAACUUUGUAGCUGCCAUCUGGAAUCC UAUUGUGGAGGCUGGGCCUAAUGUCCAUGGAACCGAACAGGGCAUGCCUCUUACC CGUGGCACUCUCAACUGGCCCGGAGGCGAUAGGAAUCGCUGGCCCUACCGCAACC AGAUUGAGGAGGGUCGCUGGUACGUGACCUUCUGGACUCAGUACGAUCCUGAUG AGUGGGUCUGGUUGGAUGAGUUCCAUCUUCAGUUCACCUUGCAGCCGGGCACGCA UGCCCCUACCGAUAACCAUCACUGGGAUAUAACAACAGAUAGUCUAGGUACUGGC CUCUGGGGCCUCCGGGAUCUUGUGUUCUACCCAAUAGGUGUUCAGCCCAGGAUAG UGAUACCCCCCACUGGGCCUACCAGCUCCCGUGUGACCUUCGACCUCCCCUCGGG UGAGGACGAUGAGUACUACACAGAUGAGGAAGGCGAGUCCGAUGAGGGAGCUGA GGAUGAUGAAGGACCCCCCCUUGAAUUUGACCACCCAUUAGACGGCGAUCUCUCG CAACCCCCCGCCGCCGUCUUGAAAGAUCUGACCUACAAGGGGCGCAAUCUCGCCA AUGAGUUGUGGAGUACGGGGGUGCCAGAUGCGAAGGCCUGGCUGGCGGGACAGA CCGUUGACCCGUCGCCAUCCUUUCGCCGCUGGCGGGAGACUUUUCAAAAAGCGCU CCAGCGUGGUGUGAAACCCCUGGAAGCGCGUGAGCUCGCUACUAGCGAGUUCCUU GCUCAAAGAGAAAGCCGCGGCCACGCCGAGUAGGAUCGAGGGUACAGCUUUCUCC CCUUGCUUUUCUGCUUCUUUCUGUGCUUUGGUGUUACUUUAGGGUGAUAUAAUU GGCAUAAAAAUUGGCAAAAAAAAAAAAAAAAAAAAA >Mouse_Astrovirus_STL_CY3_20120618_Partial (SEQIDNO:3) CUUUGGAGGGGUGGACCAAAAGCUGUUCAUGGCUAAGGCCAAACAACAACAGAA AAAUGCUACGACCGUCACCACUACAACUGUUUCUGGUGGCAGUGGUCGGCGGUCU CGCAGGCGCGCUGUACGGCGCCGCGCUGCAGGCUCUUCUAACCCCUCAACAAAGA CAACAACUGUUCGGACUGUUUUUCGCCGCAAUACCCGGCCUCGCGGUAAUCGCCG CAGGAGUAGGAAUGCUCAGCGGCAGACUCCUCGCGAGGUUGUCCAGACGGUUACG GCGACCCUCGGAACGGUGGCGCGAACCAGGGCGAUCAGGUCGAGCUUGAGAUGG CAGCGCUCCUCAGCCCAGCGCUGAUCAAGGAAACAACUGGCUCAAAUGCAUUUGG UCCACUACAGAUGUAUGCCUCCACGCAUGCCAUGUGGAGGGUGGAUAGGCUCACA CUCAAGCUCACCCCCUUGGUCGGCGCCUCCGCCGUCUCCGGUACAGCAGUUCGUG CCUCACUGAAUAUGACAUCAGGACCCGCUGCGCCCGCCUGGUCAGCUCUGGGCGC GCGGAAGCACGUGGAUACCAACCCUGGUCGGUCGGCCUCCUUCACCCUCACAGCC GCCGACAUCCCUGGCCCUAAGCAAGGUUGGUUCCUCACUAACACCAAGCAAGACG CCGGCUUCUCAGUCGGCGGGGCCAUUGAGAUCCAUACUCUCGGCAAGACAAUGUC AACCUACCAGAAUGCGCCCUACACCGGCCCACUCUUUCUUGCCGAGGUCACAGGC ACCUGGAGGUUUAAGAACUAUGAGCCCCAGCCUGGCAUGCUUAACCUCCUCAAGA CCGAGGUUAAAGAGCCUGCGGGCACUGUGAAAGUACACUCAAAGCCCGGGGAGCC UGUCACACUCUCUAUUCCUGAAGCAGGGACCUUUGCCGGCCUUGAGAGGCUAAAU CCAACAGCUUCGGCCACGCCGGGUGAGAUCAUCUGGGAGGUGGUGGACUCCGCCG CGAAUGCGGUCUCCGGACUACUCCCUCAACCCUGGCAGUGGCUCUUUAAAGGCGG CUGGUUCUUCCUGAAAAGGAUUGCCAACCGGAAACCGGUUGGUGCUGCUACUGU GGCGGGUGAACCUGAUGGAGGUGAAGUUACCUUCCGCGUCUAUGCCAGCAUCGCG GAUGCCCAGAAUGAUGUUCCUUGCAUUGCUUCCUCGCAGGCCUCUACUCAAUCCA UACAGACGCAGGGGCUUAAGAUCUCUCAAGUGACUCCUGGGACCAUUGGCAUGCC CGAAACCGCGAUUGCCACCCAUAAUAUGGUCCCACCACCUGAGUCUGGACCCUAC UACUAUCAGGGGCCCACCCUGGAGGCUGCUGCUCCCCUGAAAGCCCCCAAAUACA CACAGUGGAUACUUGUGGACGCUGGGGCUUCCCAGGAGGGGCCUCGCCUACACUC CGGGUGGUUCCAGCAGAGCAGACCUCAGCCUGGUCGAGCUGCACCUUGGAGCUC CCAGGCACCUUCCUCCAGAACAUGCAUGAGAUUGACCCCCGUGACGUUGCAGCCG GUACCUUUCCCAUCAAUCACUGGAAUGCGAACACUUCGGUGCUCACGCGGCUUGG CACCGCCUACGGUUGCAACCAAGCGCGGGUUCGCACCUCCGGGGAAGUCACGCUG GUUAUCUCCACCACUUCUGUUCUCUGGAGGGCCGAUGUCUCCAUAGGGUGGAACU AUGACAACUUCCUAGCUGCCAUCUGGUGCCCCAUUGUGGUGGCUGGGCCUGGUGU CCAUGGAACUGAACAGGGCAUGCCUCUUACCCGGGGCACUCUCAACUGGCCCGGG GGCGAUAGGAAUCGCUGGCCCUACCGUAACCAGAUUGAGGAGGGUCACUGGUAU GUGACCUUCUGGACUCAGUACGAUCCUGAUGAGUGGGUCUGGUUGGACGACUUC CACCUCCAGUUCACCUUGCAACCGGGCACGCAUACCCCCACUGAUAACCACCGCU GGGAUAUAACAACAGAUAGCUUGGGCACUGGCCUCUGGGGCCUCCGGGACCUUGU GUUCUACCCAAUAGGUGUUCAGCCCAGGAUAGUGAUACCACCCACUGGGCCUACC AGCUCCCGUGUGGUCUUCGACCUCCCCUCGGGUGAGGACGAUGAGUACUACACAG AUGAGGAAGGCGAGUCCGAUGAGGGAGCUGAGGAUGAUGAAGGAAACCCCCUUG AUUUUGACCACCCAUUAGACGGCGAUCUCUCGCAACCCCCCGCCGCCGUCUUGAA AGAUCUGACUUAUAAGGGGCGUAAUCUCGCCAAUGAGUUGUGGAGUACGGGGGU GCCAGAUGCGAAGGCCUGGUUGGCGGGACAAGCCGUUGACCCGUCGCCAUCCUUU CGCCGCUGGCGGGAGACCUAUCAAAAAGCGCUCCAGCGUGGUUUGAAACCCCUGG AAGCGCGUGAGCUCGCUACUAGCGAGUUCCUUGCUCAAAGAGAAAGCCGCGGCCA CGCCGAGUAGGAUCGAGGGUACAGCUUUCUCCCCUGCUUUUCUGCUUCUUUCUGU GCUUCUGGUGUUACUUUAGGGUGAUAUAAUUGGCAUAAAAAUUGGCAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA >Mouse_Astrovirus_STL_CY4_20120618_Partial (SEQIDNO:4) CUUUGGAGGGGUGGACCAAAAGCUGUUCAUGGCUAAGGCCAAACAACAACAGAA AAAUGCCACGACCGUCACCACUACAACUGUUUCUGGUGGCAGUGGUCGGCGGUCU CGCAGGCGCGCUGUACGGCGCCGCGCUGCAGGCUCUUCUAACCCCUCAACAAAGA CAACAACUGUUCGGACUGUUUUUCGCCGCAAUACCCGGCCUCGCGGUAAUCGCCG CAGGAGUAGGAAUGCUCAGCGGCAGACUCCUCGCGAGGUUGUCCAGACGGUUACG GCGACCCUCGGAACGGUUGGCGCGAACCAGGGCGAUCAGGUCGAGCUUGAGAUGG CAGCGCUCCUCAGCCCAGCGCUGAUCAAGGAAACAACUGGCUCAAAUGCUUUUGG UCCACUACAGAUGUAUGCCUCCACGCAUGCCAUGUGGAGGGUGGAUAGGCUCACA CUCAAGCUCACCCCCUUGGUCGGCGCCUCCGCCGUCUCCGGCACAGCAGUUCGUG CCUCACUGAAUAUGACAUCAGGACCCGCUGCGCCCGCCUGGUCAGCUCUGGGCGC GCGGAAGCACGUGGAUACCAACCCUGGUCGGUCGGCCUCUUUCACCCUCACAGCC GCCGACAUCCCUGGCCCUAAGCAAGGUUGGUUCCUCACUAACACCAAGCAAGACG CCGGCUUCUCAGUCGGCGGGGCCAUUGAGAUUCAUACUCUCGGCAAGACAAUGUC AACCUACCAGAAUGCGCCCUAUACCGGCCCACUCUUUCUUGCCGAGGUCACAGGU ACCUGGAGGUUUAAGAACUAUGAGCCCCAGCCUGGCAUGCUUAACCUCCUCAAGA CCGAGGUUAAAGAGCCUGCGGGCACUGUGAAAGUACAUUCAAAGCCCGGGGAGCC UGUCACACUUUCUAUUCCUGAAGCAGGGACCUUUGCCGGCCUUGAGAGGCUAAAU CCAACAGCCUCGGCCACGCCGGGUGAGAUCAUCUGGGAGGUGGUGGACUCCGCCG CGAAUGCGGUCUCCGGACUACUCCCUCAACCCUGGCAGUGGCUCUUUAAAGGCGG CUGGUUCUUCCUGAAAAGGAUUGCCAACCGGAAACCGGUUGGUGCUGCUACUGU GGCGGGUGAACCUGAUGGAGGUGAAGUUACCUUCCGCGUCUAUGCCAGCAUCGCG GAUGCCCAGAAUGAUGUUCCUUGCAUUGCCUCCUCGCAGGCCUCUACUCAAUCCA UACAGACGCAGGGGCUUAAGAUCUCUCAAGUGACUCCUGGGACCAUUGGCAUGCC CGAAACCGCGAUUGCCACCCAUAAUAUGGUCCCACCACCUGAGUCUGGACCCUAU UACUAUCAGGGGCCCACCCUGGAGGCUGCUGCUCCCCUGAAAGCCCCCAAAUACA CACAGUGGAUACUUGUGGACGCUGGGACUUCCCAGGAGGGGCCUCGCUUACACUC CGGGGUGGUUCCAGCAGGGCAGACCUCAGCCUGGUCGAGCUGCACCUUGGAGCUC CCAGGCACCUUUCUUCAGAACAUGCAUGAGAUUGAUCCCCGUGAUGUUGCAGCUG GCACUUUUCCCAUCAACCACUGGAACGUGCGCACCUCGACGCUUACGCGGCUUGG CAUCGCCUAUGGCUGUAAUCAGGCGCGGGUCCGCACCUAUGGGGAAGGGGUCCCG CAUGUGGUCAUUUCCACCACCUCUGUGCUCUGGAGGGCCGAUGUCUCCGAAGGCU GGAACUAUGACAACUUUCUUGCUGCCAUCUGGAAUCCCAUUGUGGAGGCUGGGCC CUCCACCCAUGGAACUGAACAGGGUGUGCCUCUUACCCGGGGCACUCUCAACUGG CCCGGGGGUGAUAGAAAUCGCUGGCCCUACCGCAACCAGGUUGAGGAAGGUCACU GGUACGUGACCUUCUGGACUCAGUACGAUCCUGAUGAGUGGGUCUGGUUGGAUG AGUUCAAUCUCCAGUUCACCUUGCAGCCCGGCAACCACACCCCUACUGCUAACCA CCACUGGGAUAUAACAACAGAUAGCUUAGGCACUGGCCUCUGGGGCCUCCGGGAC CUUGUGUUCUAUCCAAUAGGUGUCCAGCCCAGGAUAGUGAUACCGCCUACUGGGC CUACUAGCUCCCGUGUGACCUUCGACCUCCCCUCGGGUGAGGACGAUGAGUAUUA CACAGAUGAGGAAGGCGAGUCCGAUGAGGGAGCUCAGGAUGAUGAAGGGAAUCC CCUUGAAUUUGACCAUCCAUUAGACGGCGAUCUCUCGCAACCCCCCGCCGCCGUC CUGAAAGAUCUAACCUACAAGGGGCAAAAUCUCGCCAAUGAGUUGUGGAGUACG GGGGUGCCAGAUGCGAAGGCCUGGCUGGCGGGGCAGACUGUUGACCCGUCGCCAU CCUUUCGCCGCUGGCGGGAGACCUUUCAAAAAGCGCUCCAGCGUGGUGGUAAAGCC CCUGGAAGCGCGAGAACUCGCCACCAGCGAGUUCCUUGCUCAAAGAGAAAGCCGC GGCCACGCCGAGUAGGAUCGAGGGUACAGCUUUCUCUCCCCGCUUUUCUGCUCCU UUUCUGUGCUUUUGGUGUUACUUUAGGGUGAUAUAAUUGGCAUAAAAAUUGGCA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

(18) Oligonucleotides of the present teachings, which include but are not limited to oligonucleotides which can serve as probes and/or primers for detecting a murine astrovirus, include the following non-limiting examples:

(19) TABLE-US-00003 (SEQIDNO:5) CUUUGGAGGGGAGGACCAAAAGCUCUUCAUGGGC; (SEQIDNO:6) CCAAGAAAGAGGCACTAGTGGCACTC; (SEQIDNO:7) GTTTTTTTTTTTTTTTTTTTTTGCCAATTTTTATGCCAATTATATCACC C; (SEQIDNO:8) TACATCGAGCGGGTGGTCGC; (SEQIDNO:9) GTGTCACTAACGCGCACCTTTTCA; and (SEQIDNO:10) TTTGGCATGTGGGTTAA.

(20) In various aspects, an oligonucleotide can be RNA, DNA or a synthetic analogue such as a peptide nucleic acid. In various aspects, an oligonucleotide of the present teachings can further comprise one or more labels, such as a fluorophore, a fluorescence quencher, a hapten such as biotin, or a radioisotope such as .sup.33H, .sup.14C, .sup.32P, .sup.33P, .sup.35S, or .sup.125I.

(21) Oligopeptides of the present teachings, which include but are not limited to peptides that can serve as antigens for a vaccine, an antibody or a serum conversion assay, or a competitive probe for an antibody-based assay such as a radioimmunoassay include, without limitation,

(22) TABLE-US-00004 (SEQIDNO:11) CGGDRNRWPYRNQIE and (SEQIDNO:12) CSEFLAQRESRGHAE.

EXAMPLES

(23) The present teachings including descriptions provided in the Examples that are not intended to limit the scope of any claim or aspect. Unless specifically presented in the past tense, an example can be a prophetic or an actual example. The following non-limiting examples are provided to further illustrate the present teachings. Those of skill in the art, in light of the present disclosure, will appreciate that many changes can be made in the specific embodiments that are disclosed and still obtain a like or similar result without departing from the spirit and scope of the present teachings.

Example 1

(24) This example demonstrates the detection of astroviruses using next generation sequencing.

(25) In these experiments, to examine the mouse virome in an unbiased manner, fecal RNA and DNA libraries from three immunocompetent C57BL/6 (B6) mice were generated. The fecal RNA and DNA libraries were sequenced using 454 (pyrosequencing) technology (Roche) and VirusHunter was used to analyze the resulting reads. 100 mg of frozen stool was chipped and then resuspended in 6 volumes of PBS (Finkbeiner, S. R., et al., PLoS. Pathog. 4: e1000011, 2008). The sample was centrifuged to pellet particulate matter and the supernatant was then passed through a 0.45 m filter. Total nucleic acid was isolated from 200 L primary stool filtrate using AMPLIPREP DNA extraction machine (Roche) according to manufacturer's instructions. To enable subsequent detection of both RNA and DNA viruses, total nucleic acid from each sample was reverse transcribed and amplified as previously described (Wang, D., et al., PLoS Biol. 1: E2, 2003). Briefly, RNA templates were reverse transcribed using primerA containing a 16-nucleotide specific sequence followed by 9 random nucleotides for random priming. The 16-nucleotide specific sequence is unique for each sample and served as a barcode in assigning sequencing reads to a sample. SEQUENASE (United States Biochemical) was used for second strand cDNA synthesis and for random-primed amplification of DNA templates using PrimerA. Each sample was then subjected to 40 cycles of PCR amplification using PrimerB containing the same 16 nucleotide specific sequence as in the corresponding PrimerA. Amplification products were pooled, adaptor-ligated and sequenced at the Washington University Genome Sequencing Center on the 454 GS-FLX platform (454 Life Sciences).

(26) Sequences were analyzed using customized pipeline VirusHunter as described (Zhao, G., et al., J Virol. 85: 10230-8, 2010. Briefly, sequence reads were assigned to samples based on the unique barcode sequences (i.e. PrimerB sequences). For further analysis, primer sequences were trimmed off and the sequence reads were clustered using CD-HIT (Li, W., and Godzik, A., Bioinform. 22: 1658-9, 2006) to identify redundant reads. Sequences were clustered on the basis of 95% identity over 95% sequence length, and the longest sequence from each cluster was picked as the representative sequence. Then, unique sequences were masked by REPEATMASKER (Institute for Systems Biology). If a sequence did not contain a stretch of at least 50 consecutive non-N nucleotides or if greater than 40% of the total length of the sequence is masked, it was removed from further analysis (i.e., filtered). Good quality sequences after filtering were sequentially compared against (i) the human genome using BLASTn; (ii) GenBank nt database using BLASTn; (iii) GenBank nr database using BLASTx (Altschul, S. F., et al., J. Mol. Biol. 215: 403-10, 1990); Minimal e-value cutoffs of 1e-10 and 1e-5 were applied for BLASTn and BLASTx, respectively. Sequences were phylotyped as human, mouse, fungal, bacterial, phage, viral, or other based on the identity of the top BLAST hit. Sequences without any significant hit to any of the databases were placed in the unassigned category. If a sequence aligns to both a virus and other kingdom (e.g. bacteria or fungi) with the same e value it is classified as ambiguous. All eukaryotic viral sequences were further classified into viral families based on the taxonomy ID of the best hit.

(27) All viral sequences and unassigned sequences from each sample were assembled into contigs using NEWBLER (454 Life Sciences) with default parameters. Sample 31H_B6_CR6 and 31H_B6_untreated were sequenced twice. Both sequencing data from each sample were used to try to obtain the best assembly.

(28) 132 astrovirus sequences were identified: 21, 76, and 35 from mouse A, B, and C, respectively. No other viral reads were identified. The viral and unassigned reads detected in the feces of mouse B were used to assemble a 6,748-nucleotide (nt) contig with 9-fold coverage. A BLASTn (Altschul, S. F., et al., J. Mol. Biol. 215: 403-10, 1990) search of the NCBI nt database identified this contig to be a highly divergent astrovirus with at most 60% amino acid identity to Human Astrovirus 6 isolate Katano (FIG. 1). Reads detected in the feces of mouse C were used to assemble four contigs ranging from 288 to 3095 nt with 99.0-99.7% nt identity to the 6,748-nt contig from mouse B. Reads detected in the feces of mouse A were used to assemble three contigs ranging from 1024 to 2463 nt with 89.1-95.2% identity to mouse B contig00001 (FIG. 1). These data show the presence of at least two unidentified astroviruses in a specific-pathogen free research facility.

Example 2

(29) This example illustrates the generation and sequencing of full-length murine astrovirus genomes.

(30) In these experiments, subsequent analysis of the fecal specimens from mouse B and mouse C utilizing rapid amplification of cDNA ends (RACE) reactions and traditional Sanger sequencing generated the complete consensus genomes of the two mouse astroviruses: MoAstV STL CY1 and MoAstV STL CY2 (FIG. 2).

(31) Total RNA was extracted from the murine stool samples previously used in the deep sequencing reaction using an RNEASY mini kit (Qiagen, Valencia, Calif.). One microgram of RNA was used as the template for Rapid Amplification of cDNA Ends (RACE) reactions to generate the 5 and 3 genome ends using 5 RACE and 3 RACE kits (Invitrogen, Carsbad, Calif.) according to the manufacturer's instructions. To generate full genomic sequences, one microgram of RNA was used as the template for cDNA synthesis using the SUPERSCRIPT III first-strand synthesis kit and an oligo(dT).sub.12-20 primer (Invitrogen) according to the manufacturer's instructions. Full genomic sequences were then amplified using ELONGASE Enzyme Mix (Invitrogen) and primers 5-CCAAGAAAGAGGCACTAGTGGCACTC-3 (SEQ ID NO:6) and 5-GTTTTTTTTTTTTTTTTTTTTTGCCAATTTTTATGCCAATTATATCACCC-3 (SEQ ID NO:7). The 6.7 kb PCR product was gel purified and ligated into a pCR4-TOPO TA sequencing vector (Invitrogen). Universal M13 forward and reverse primers were used for sequencing, and primer walking was applied as needed. Four clones with 2 to 4-fold redundancy each were used to construct consensus sequence 1 using GENEIOUS Pro v5.0 (Biomatters Ltd.) (Bosma, M. J., and Carroll, A. M., Ann. Rev. Immun. 9: 323-50 m 1991). Three clones with 2 to 4-fold redundancy each were used to construct consensus sequence 2. Predicted ORFs were identified using GENEIOUS. Protein motifs were predicted using Pfam (Finn, R. D., et al., Nuc. Acid. Res. 38: D211-D222, 2010).

(32) Comparison of the MoAstV STL CY1 genome to contig B1 generated by 454 pyrosequencing showed 99.9% nt identity, demonstrating that they are the same virus. Comparison of the MoAstV STL CY2 genome to contigs A00001, A00002, and A00010 generated by 454 pyrosequencing showed 99.6-99.9% nt identity, demonstrating that they are the same virus.

Example 3

(33) This example illustrates that the MoAstV STL genome organization is consistent with other mamastroviruses.

(34) In these experiments, the complete genome length of MoAstV STL CY1 and MoAstV STL CY2 was 6,817 nt, excluding the poly-A tail. MoAstV STL CY1 and MoAstV STL CY2 were predicted to contain a 5 untranslated region (UTR), three open reading frames (ORF 1a, 1b, and 2), a 3 UTR, and a polyA tail. The 5 and 3 UTR were determined to be 46 and 90 nt in length, respectively.

(35) ORF1a of MoAstV STL CY1 and MoAstV STL CY2 was predicted to encode a 928 as protein containing a trypsin-like peptidase domain and showed significant similarity to known astroviruses by BLASTP (Altschul, S. F., et al., J. Mol. Biol. 215: 403-10, 1990). The 58-nt ORF1a/1b junction of MoAstV STL CY1 and MoAstV STL CY2 contained the heptanucleotide frameshift signal (AAAAAAC) conserved in all astroviruses (De Benedictis, P., et al., Infect. Genet. Evol. 11: 1529-44, 2011; Jiang, B., et al., P. Natl. Acad. Sci. USA. 90: 10539-43, 1993; Lewis, T. L. and Matsui, S. M., Arch. Virol. 140:1127-35, 1995; Mendez, E. and Arias, C. F., Fields Virology, 5.sup.th ed. p. 981-99, 2007). Furthermore FSFinder analysis (Moon, S., et al., Nucleic. Acids. Res. 32: 4884-92, 2004) confirmed that the downstream sequence was capable of generating a stem-loop structure required for a 1 ribosomal frameshift to lead to ORF lab translation (Brierley, I., et al., Biochem. Soc. T. 36: 684-9, 2008; Giedroc, D. P. and Cornish, P. V., Virus Res. 139: 193-208, 2009; Mendez, E. and Arias, C. F., Fields Virology, 5.sup.th ed. p. 981-99, 2007). The first amino acid in frame with the frameshift signal was predicted to be the start position for ORF1b of MoAstV STL CY1 and MoAstV STL CY2. ORF1b of MoAstV STL CY1 and MoAstV STL CY2 is predicted to encode a 502 as protein containing an RNA dependent RNA polymerase (RdRP) domain, consistent with other astroviruses (De Benedictis, P., et al., Infect. Genet. Evol. 11: 1529-44, 2011; Mendez, E. and Arias, C. F., Fields Virology, 5.sup.th ed. p. 981-99, 2007).

(36) MoAstV STL contained a sequence upstream of ORF2highly conserved among mammalian astrovirusesCUUUGGAGGGGAGGACCAAAAGCUCUUCAUGGGC (SEQ ID NO: 5), which encompasses the ORF2 start codon (in bold) and is suggested to be a promoter for sgRNA synthesis (Mendez, E. and Arias, C. F., Fields Virology, 5.sup.th ed. p. 981-99, 2007; Walter, J. E., et al., Arch. Virol. 146: 2357-67, 2001). As in most other mamastroviruses (De Benedictis, P., et al., Infect. Genet. Evol. 11: 1529-44, 2011), MoAstV STL had an 8-nt region of overlap at the end of ORF1b and beginning of ORF2, with ORF2 maintained in the same frame as ORF1a. ORF2 of MoAstV STL CY1 and MoAstV STL CY2 was predicted to encode an 819-aa protein containing the structural capsid protein.

(37) Collectively, these data demonstrate that the genome organization of MoAstV STL CY1 and MoAstV STL CY2 is consistent with other members of the Astroviridae family, and the mamastrovirus genus in particular.

Example 4

(38) This example illustrates that MoAstV STL viruses are members of a new mamastrovirus genogroup.

(39) In these experiments, to evaluate the relationship between MoAstV STL CY1 and MoAstV STL CY2 and other known astroviruses, phylogenetic analysis was performed using aa sequences predicted to correspond to the capsid-containing ORF2. Analyses performed for ORF1a and 1b showed similar relationships. In all analyses, MoAstV STL clustered with the mamastrovirus genus and not the avastrovirus genus.

(40) Sequences from astrovirus genomic segments encoding ORF1a, 1b, and 2 were translated. These sequences were aligned using ClustalX 2.0.12 (Larkin, M. A., et al., Bioimform. 23: 2947-8, 2007). Phylogenetic inference was performed with maximum parsimony using PAUP 4b10 and maximum likelihood using RAxML (Stamatakis, A., Bioimform. 22; 2688-90, 2006) and BLOSUM62 transition matrix methods with 1000 bootstrap replicates. The resulting phylogenetic trees were visualized using FIGTREE 1.3.1 (Andrew Rambaut), MEGA 5.05 was used for distance estimation (uncorrected p-distance) (Tamura, K., et al., Mol. Biol. Evol. 28: 2731-9, 2011).

(41) The MoAstV STL viruses were most closely related to a clade of recently characterized porcine and wild boar astroviruses, but shared only 33-36% amino acid identity in the capsid region and 63-67% amino acid identity in the RdRp region. This genetic grouping also included the recently deposited mouse astrovirus sequence derived from laboratory mice in Cincinnati, murine astrovirus strain TF18LM but was highly divergent from mouse astrovirus M-52/USA/2008, previously detected in wild mice (Phan, T. G., et al., PLoS Pathog. 7: e1002218, 2011).

(42) In analyses of ORF2, the MoAstV STL viruses formed a distinct genetic cluster with a mean amino acid genetic distance (p-dist) of 0.7620.010 and 0.7890.010 to mamastrovirus genogroups I and II, respectively. Intra-group p-dists were 0.5480.010, 0.6290.011, and 0.6410.009 for mamastrovirus genogroups I, II, and the MoAstV STL genetic cluster, respectively.

(43) Collectively, these data demonstrate that MoAstV STL is a mammalian astrovirus and is likely a member of a new third genogroup of mamastroviruses.

Example 5

(44) This example illustrates that adaptive immunity is required to control MoAstV replication.

(45) In these experiments, since MoAstV STL CY1 and MoAstV STL CY2 were originally identified in the feces of asymptomatic B6 mice, whether MoAstV STL was present in the feces of other mice from the same specific-pathogen free research mouse colony was examined. First, astrovirus was detected in immunocompromised mice in the cleanest barrier facility by PCR (FIG. 3). In FIG. 3, B-cell deficient mice are labeled MuMT and RAG deficient mice are labeled B6 RAG. To quantify the number of MoAstV STL CY1 and MoAstV STL CY2 genome copies in tissues and feces, a Taqman-based quantitative reverse transcriptase PCR (qRT-PCR) assay was designed (FIG. 4a), which targeted a 72-bp region of the RdRP conserved between MoAstV STL CY1 and MoAstV STL CY2.

(46) Total RNA was extracted from individual stool pellets using an RNeasy mini kit (Qiagen) or from tissue samples using Trizol reagent (Invitrogen). One tenth of the total stool RNA or 1 g of tissue RNA was reverse transcribed using ImpromII RT (Promega, Madison, Wis.) and random primers (Invitrogen) to yield cDNA. Triplicate qPCR reactions were performed using one tenth of the cDNA, primers specific to an 80 nt region of ORF1b (sense: 5-TACATCGAGCGGGTGGTCGC-3 (SEQ ID NO: 8); antisense: 5-GTGTCACTAACGCGCACCTTTTCA-3) (SEQ ID NO: 9), and a Taqman probe (Applied Biosystems, Foster City, Calif.) with the sequence 5-TTTGGCATGTGGGTTAA-3 (SEQ ID NO:10) containing a 5 6-carboxyfluorescein (6FAM) dye label, 3 nonfluorescence quencher (NFQ) and minor groove binder (MGB). The number of genome copies per sample was determined by comparison to a standard curve (generated by a 10-fold dilution of target-containing-plasmid in tRNA (Invitrogen)). For stool samples, the number of genome copies per sample was multiplied by 100 to account for dilution from total RNA originally extracted from the stool pellet and are reported as genome copies per stool pellet.

(47) Across multiple experiments, the assay was able to repeatedly detect from 10.sup.6 to 10.sup.1 genome copies, and 1 genome copy was detected in 2 of 3 technical replicates consistent with Poissan distribution statistics, suggesting that this assay was both sensitive and robust.

(48) Given that previous human studies have implicated the adaptive immune system as essential in the control of astrovirus pathogenesis (Wood, D. J., et al., J. Med. Virol. 24:435-44, 1988), the number of astrovirus genome copies were measured in the feces of mice deficient in B and T cells due to a mutation in Recombination Activating Gene 1 [RAG1, (Mombaerts, P., et al., Cell. 68: 869-77, 1992). While these mice exhibited no overt signs of illness, up to 10.sup.9 astrovirus genome copies per fecal pellet were detected and notably, 21/21 RAG.sup./ mice screened were positive for astrovirus. These data suggest that adaptive immunity is essential for restricting MoAstV replication.

Example 6

(49) This example illustrates that innate and adaptive immunity contributes to the control of MoAstV replication.

(50) In these experiments, to assess the relative hierarchy of innate and adaptive immunity in restricting MoAstV replication, the timecourse of natural astrovirus infection in B6 and RAG1.sup./ mice were examined, as well as mice deficient in STAT1.sup./ (STAT1.sup./). C57BL/6J, B6.RAG1.sup./, and STAT1.sup./ mice were bred and housed in an enhanced barrier specific-pathogen-free facility at Washington University in St. Louis in compliance with federal and institutional guidelines (Cadwell, K., et al., Cell. 141: 1135-45, 2010). All studies were performed using age-matched female mice between eight and ten weeks of age. Three mice, one of each genotype, were cohoused on day 0, and fecal samples were collected every 2 days to follow astrovirus shedding. Mice were euthanized on day 14 and tissues were harvested for analysis.

(51) As previous studies have shown that astrovirus infections can spread beyond the gastrointestinal tract (Blomstrm, A. L., et al., J. Clin. Microbiol. 48: 4392-6, 2010; Quan, P. L., et al., Emerg. Infect. Dis. 16: 918-25, 2010), the distribution of MoAstV was investigated in multiple tissues as well as feces. In order to address the potential presence of additional astrovirus strains that might not be detectable by the TAQMAN assay, B6, STAT1.sup./, and RAG1.sup./ mice were cohoused for 14 days to ensure infection by the same viruses occurred.

(52) High levels of MoAstV shedding in fecal samples were observed in RAG1.sup./ mice at day 0 and at all timepoints tested (FIG. 4b). In contrast, low levels of MoAstV were observed in the feces of both B6 and STAT1.sup./ mice at day 0, prior to cohousing. Two days of cohousing, elevated levels of MoAstV genome copies were detected in feces from B6 and STAT1.sup./ mice, with STAT1.sup./ mice shedding significantly more MoAstV than B6 mice at day 2 (p<0.05). Overall, MoAstV shedding over the course of the experiment differed significantly by genotype (p<0.0001 for all combinations).

(53) The tissue distribution of MoAstV STL was analyzed after 14 days of cohousing. High levels of genome copies in the GI tract of RAG1.sup./ mice were detected (FIG. 4c), consistent with the observation that RAG1.sup./ mice shed up to 10.sup.9 genome copies per stool pellet. The quantity of viral genome copies detected in the GI tract of B6 and STAT1.sup./ mice were significantly lower than in the RAG1.sup./ mice (p<0.001 for all GI tract tissues tested). While MoAstV RNA was detected in the liver and kidney of RAG1.sup./ mice, it was not detected in the liver or kidney of B6 or STAT1.sup./. A limited number of genome copies in the spleen of STAT1.sup./ mice were detected, twice as many as observed in the spleen of wild-type mice, though this comparison was not statistically significant. MoAstV STL was undetectable in the brain of any mouse tested, in contrast to previously identified enteric mouse pathogens in immunocompromised mice (Karst, S. M., et al., Science. 299: 1575-8, 2003).

(54) These data demonstrate a role for both the innate and adaptive immune systems in the control of astrovirus infection and replication.

Example 7

(55) This example illustrates that MoAstV is present in mice from commercial mouse colonies.

(56) In these experiments, the presence of MoAstV in mice available from commercial vendors was assessed. Since extremely high levels of MoAstV STL in the feces of RAG1.sup./ mice were previously observed, the present inventors decided to assess the presence of MoAstV STL in commercially available mice lacking B and T cells. RAG1.sup./ mice (B6.129S7-Rag1.sup.tm1Mom/J, cat #002216) were purchased from The Jackson Laboratory, RAG2.sup./ mice (129S6/SvEvTac-Rag2.sup.tm1Fwa, cat#RAG2-F) (Shinkai, Y., et al., Cell. 68: 855-67, 1992) from Taconic facility IBU25, and SCID mice (CB17/Icr-Prkdc.sup.scid/IcrCrl, cat#236) (Bosma, M. J., and Carroll, A. M., Ann. Rev. Immun. 9: 323-50 m 1991) from Charles River facility W09the three major mouse vendors in the United States. Mice were sacrificed immediately upon arrival and samples were collected for analysis.

(57) Consistent with previous findings (FIG. 4), extremely high levels of MoAstV STL were observed in fecal and tissue samples from RAG1.sup./ and RAG2.sup./ mice (FIG. 5). MoAstV was undetectable in the feces or tissues of SCID mice. Overall, however, these data suggest that MoAstV STL is a common pathogen, likely present in many research mouse facilities in the United States.

Example 8

(58) This example illustrates antibody responses during murine astrovirus infection.

(59) In these experiments, B6 mice were inoculated with MuAstV or mock-inoculated. Serum antibody responses measured at 16 days. Differences in MuAstV-specific antibodies were observed between MuAstV- and mock-inoculated mice (p<0.02; Mann-Whitney test) (FIG. 6).

(60) The astrovirus capsid protein can assemble into virus-like particles (VLP) which share biological properties of virions. A baculovirus system was used to express the capsid protein of MuAstV strain STL 2. The ability of MuAstV VLP to detect serum antibodies specific to MuAstV by ELISA were validated using MuAstV VLP compared to MNV virions, as well as MuAstV and MNV-inoculated mice (data not shown). Using this assay, an elevation of virus-specific antibodies was observed in the serum of MuAstV-inoculated mice compared to mock-inoculated control mice (FIG. 6). These data demonstrate that VLP derived from the sequence of the capsid protein of MuAstV STL2 can detect a serological response to MuAstV infection, which can be used for the establishment of MuAstV-free mice.

Example 9

(61) This example illustrates the prevalence of murine astrovirus in a specific pathogen-free breeding facility.

(62) Fecal pellets were obtained from mice from Dec. 4, 2011-Jan. 15, 2012 and the presence of murine astrovirus tested by quantitative RT-PCR. Limit of detection=100 genome copies/fecal pellet. Mice were housed 1-5 mice/cage, on 7 racks in 1 breeding room. Bedding sentinels were housed 2 mice/cage, 1 cage/rack in the same room.

(63) MuAstV sequences were detected by next generation sequencing or quantitative PCR (qPCR) in the feces of mice from at least six research institutions and two commercial vendors. Furthermore, MuAstV was detected by qPCR in 73% of mouse lines in a single breeding room at Washington University School of Medicine (Table. 1). These results demonstrate that the prevalence of MuAstV in laboratory mice can be equal to or greater than that of murine norovirus (MNV), which is the most prevalent, recognized viral agent in laboratory mice today.

(64) TABLE-US-00005 TABLE 1 Mice Sentinels # of # of # of # of # of # of mice cages lines racks mice cages MuAstV positive 122 72 32 7 5 3 Total tested 485 178 44 7 14 7 Prevalence of MuAstV 25% 40% 73% 100% 36% 43%

Example 10

(65) This example illustrates genetic diversity of murine astroviruses identified by next-generation sequencing.

(66) Virus contigs from fecal samples (red) were aligned with known (black) MuAstV sequences using ClustalW. A maximum-likelihood phylogenetic tree was generated using MEGA.

(67) Shotgun sequencing of libraries of RNA and DNA isolated from 35 fecal samples from laboratory rodents using the 454 GS FLX Titanium platform generated an average of 31,781 high quality reads per sample. The virome was examined using VirusHunter. Sequences with 76-99% nucleotide (nt) identity to MuAstV strain STL 1 were detected in mouse samples (example sequences illustrated in FIG. 7). These data demonstrate that MuAstV can be genetically diverse.

Example 11

(68) This example illustrates kinetics of murine astrovirus shedding.

(69) In these experiments, C57BL/6 (B6) and STAT1.sup./ mice were inoculated with MuAstV and shedding in feces was measured. RAG1.sup./ mice were naturally infected with MuAstV and shedding in feces measured for 14 days. Differences in MuAstV shedding were observed between B6 and STAT1.sup./ mice at 6-12 days (p<0.05; one way ANOVA); significant differences in MuAstV shedding were observed between B6 and RAG1.sup./ mice, STAT1.sup./ and RAG1.sup./ mice at all time points (p<0.05; one way ANOVA).

(70) Experiments using naturally-infected RAG1.sup./ mice co-housed with B6 and STAT1.sup./ mice suggest that both innate and adaptive immunity control MuAstV replication. Since the high level, sustained shedding observed in RAG1.sup./ mice may confound the kinetics of MuAstV replication and clearance in co-housed B6 and STAT1.sup./ mice, MuAstV shedding in B6 and STAT1.sup./ mice orally inoculated with a filtered fecal stock of MuAstV containing 510.sup.5 genome copies of MuAstV was re-examined (FIG. 8). Peak MuAstV shedding was reached 6 days after inoculation in B6 and STAT1.sup./ mice. MuAstV shedding was elevated in STAT1.sup./ mice compared to B6 mice confirming a role for innate immunity in control of MuAstV replication (FIG. 8). MuAstV shedding declined to baseline in B6 and STAT1.sup./ mice 16 days after inoculation (FIG. 8), demonstrating that innate immunity can not necessarily be required to control MuAstV clearance.

Example 12

(71) This example illustrates specificity of an ELISA for Astrovirus (AstV) virus-like particles (VLP), and that an ELISA can be used to detect AstV-specific antibodies in mice previously infected with AstV.

(72) Astrovirus VLP generationThe astrovirus capsid protein can assemble into virus-like particles (VLP) which share the biological properties of virions (Moser, L., et. al., J. Virol. 81:11937-45, 2007). To generate virus-like particles, cDNA corresponding to ORF2 of STL CY2 was tagged with a 3 TEV recognition site and 6His tag and cloned into a pFastBac1 donor vector (Invitrogen) for baculovirus expression. Protein was generated and astrovirus VLPs were purified.

(73) Astrovirus ELISA validationELISA plates were coated with serial dilutions of astrovirus VLPs and blocked with 3% BSA prior to use. Serum samples from mock and infected mice were added to the ELISA plate at a 1:100 dilution. Astrovirus VLP-specific antibodies were detected by goat-anti-mouse HRP antibodies (Jackson Immunoresearch) and ABTS peroxidase substrate (ThermoScientific) Signal was detected using a BioRad IMARK microplate reader at 415 nm. Based on the interpolated standard curve (FIG. 9), a concentration of 0.1 ng/L astrovirus VLPs was selected for use in future experiments.

(74) To further test for specificity, ELISA plates were coated with astrovirus VLPs or UV-inactivated murine norovirus MNV virions. Serum samples from mock, AstV-infected, and MNV-infected mice were analyzed. The data (FIG. 10) validate specificity of the test.

(75) Astrovirus ELISA screenC57BL/6J mice were orally inoculated on days 0 and/or 18 with 5e5 genome copies of a heterogeneous AstV solution or PBS (mock infected). At day 34 post infection, serum was collected for analysis by ELISA. (FIG. 11). The data illustrate detection of murine astrovirus antibodies by ELISA.

(76) All references cited herein are incorporated by reference, each in its entirety. Applicant reserves the right to challenge any conclusions presented by the authors of any reference.